Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Resolv ER may remedy leading causes of blindness in adults
The service has already been initiated in Maharashtra but being net-based it is easily available for patients all across the country
Adds five years of market exclusivity on approval
Proprietary implant-to-implant (i2i) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
New instrument helps maximize lab productivity and extends FTIR to large, heavy samples
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Subscribe To Our Newsletter & Stay Updated
